Identification of PTCH1 requirement for influenza virus using random homozygous gene perturbation

American Journal of Translational Research

Volumn 1, Issue 3, 2009, Pages 259-266

  Li, Wu Bo ^a   Zhu, Jie ^a   Hart, Brit ^a   Sui, Baoquan ^a   Weng, Ke ^a   Chang, Shaojing ^a   Geiger, Rebecca ^b   Torremorell, Monserrat ^b   Mileham, Alan ^b   Gladney, Christy ^b   Mellancamp, Martha A ^b,c   Li, Limin ^a   Yunus, Abdul ^a   Goldblatt, Michael ^a   Kinch, Michael S ^a  

^a Functional Genetics Inc   (United States)

^b GENUS PLC   (United States)

^c Ralco Nutrition Inc   (United States)

Author keywords

Influenza virus; PTCH1; Random homozygous gene perturbation (RHGP); Resistance to therapies; SiRNA

Indexed keywords

ANTIBODY; PROTEIN PATCHED 1; SMALL INTERFERING RNA;

ANALYTIC METHOD; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DISEASE RESISTANCE; GENE TECHNOLOGY; GENETIC VARIABILITY; GENOTYPE; HOST CELL; HUMAN; HUMAN CELL; INFLUENZA; INFLUENZA VIRUS; MORBIDITY; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN TARGETING; RANDOM HOMOZYGOUS GENE PERTURBATION; SINGLE NUCLEOTIDE POLYMORPHISM; SWINE; VIRUS RESISTANCE; WEIGHT GAIN;

ORTHOMYXOVIRIDAE;

EID: 77953433352     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ and Fukuda K. Mortality associated with influenza and respiratory syncytial virus in the United States. Jama-Journal of the American Medical Association 2003; 289: 179-186.
2. Belongia E, Kieke B, Coleman L, Donahue J, Irving S, Meece J, Vandermause M, Shay D, Gargiullo P, Balish A, Foust A, Guo L, Lindstrom S, Xu X, Klimov A, Bresee J and Cox N. Interim within-season estimate of the effectiveness of trivalent inactivated influenza vaccine - Marshfield, Wisconsin, 2007-08 influenza season (Reprinted from vol 57, pg 393-398, 2008). Jama-Journal of the American Medical Association 2008; 299: 2381-2384.
3. Hayden F, Klimov A, Tashiro M, Hay A, Monto A, McKimm-Breschkin J, Macken C, Hampson A, Webster RG, Amyard M and Zambon M. Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses (vol 10, pg 873, 2005). Antiviral Therapy 2006; 11: 130-130.
4. Luscher-Mattli M. Influenza chemotherapy: a review of the present state of art and of new drugs in development. Archives of Virology 2000; 145: 2233-2248.
5. Fox JL. Antivirals become a broader enterprise. Nature Biotechnology 2007; 25: 1395-1402.
6. Tan SL, Ganji G, Paeper B, Proll S and Katze MG. Systems biology and the host response to viral infection. Nature Biotechnology 2007; 25: 1383-1389.
7. Lamb RA and Takeda M. Death by influenza virus protein. Nature Medicine 2001; 7: 1286-1288.
8. Sui B, Bamba D, Weng K, Ung-Medoff H, Van Dyke J, Goldblatt M, Duan R, Kinch MS and Li W-L. The Use of Random Homozygous Gene Perturbation to Identify Novel Host-Oriented Targets for InfluenzaThe Use of Random Homozygous Gene Perturbation to Identify Novel Host-Oriented Targets for Influenza. Virology 2009; In Press:
9. Ge Q, McManus MT, Nguyen T, Shen CH, Sharp PA, Eisen HN and Chen JZ. RNA interference of influenza virus production by directly targeting rnRNA for degradation and indirectly inhibiting all viral RNA transcription. Proceedings of the National Academy of Sciences of the United States of America 2003; 100: 2718-2723.
10. Toftgard R. Hedgehog signalling in cancer. Cellular and Molecular Life Sciences 2000; 57: 1720-1731.
11. Lindstrom E, Shimokawa T, Toftgard R and Zaphiropoulos PG. PTCH mutations: Distribution and analyses. Human Mutation 2006; 27: 215-219.
12. Katoh Y and Katoh M. Hedgehog signaling pathway and gastric cancer. Cancer Biology & Therapy 2005; 4: 1050-1054.
13. Reiske H, Sui B, Ung H, Donahue R, Li W-L, Goldblatt M, Li L and Kinch MS. Identification of Annexin A13 as a Regulator of Chemotherapy Resistance Using Random Homozygous Gene Perturbation. Analytical Quantitative Cytology Histology 2009; In Press: